Prorenone | 40574-52-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Prorenone
• 英文别名: 3'H-Cyclopropa(6,7)pregna-4,6-diene-21-carboxylic acid, 6,7-dihydro-17-hydroxy-3-oxo-, gamma-lactone, (6alpha,7alpha,17alpha)-；(1'R,2'R,4'R,5R,10'R,11'S,14'S,18'S)-10',14'-dimethylspiro[oxolane-5,15'-pentacyclo[9.7.0.02,4.05,10.014,18]octadec-5-ene]-2,7'-dione
• CAS: 40574-52-5
• 化学式: C₂₃H₃₀O₃
• 分子量: 354.489
• InChiKey: RRHHMFQGHCFGMH-VAFIVCJBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Prorenone 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 1,4-二氧六环 、 二甲基亚砜 为溶剂， 反应 25.0h， 生成 3-<1α,2α,6β,7β-bis(methylene)-17β-hydroxy-3-oxo-4-androsten-17α-yl>propionic acid γ-lactone
  参考文献：
  名称：

  Structure-activity relationship study of spirolactones. Contribution of the cyclopropane ring to antimineralocorticoid activity

  摘要：

  A series of spirolactones containing a cyclopropane ring in the molecule was examined for its effects on the mineralocorticoid receptor. The results were compared with those of a similar series of spirolactones in which the cyclopropane ring was replaced by a double bond. Insertion of a double bond or an alpha-cyclopropane ring into the 1,2 or the 6,7 position leads to a reduction in the binding affinity. The pi-bonding system of the beta-cyclopropane ring at C-6 and C-7 does not promote binding to the receptor. The presence of the 6 beta, 7 beta-cyclopropane ring may deter metabolic activation to account for the enhanced in vivo activity.

  DOI：

  10.1021/jm00141a020
• 作为产物：
  描述：

  在 potassium tert-butylate 、 甲基磺酰氯 、 lithium tri-t-butoxyaluminum hydride 作用下， 以 四氢呋喃 为溶剂， 生成 Prorenone
  参考文献：
  名称：

  立体定向合成von6β，7β-亚甲基-3-氧代-17α-pregn-4-en-21,17-碳内酯

  摘要：

  DOI：

  10.1016/s0040-4039(01)91321-8

文献信息

• Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer
  申请人：St. Jude Children's Research Hospital, Inc.

  公开号：US10286000B2

  公开（公告）日：2019-05-14

  The invention is directed to the use of Retinoid X Receptor-gamma (RXR-gamma) agonists and Retinoid X Receptor-alpha (RXR-alpha) antagonists in treatment of cancer.

  本发明涉及视黄醇 X 受体-γ（RXR-γ）激动剂和视黄醇 X 受体-α（RXR-α）拮抗剂在治疗癌症中的应用。
• RETINOID X RECEPTOR-GAMMA AGONISTS AND RETINOID X RECEPTOR-ALPHA ANTAGONISTS FOR TREATMENT OF CANCER
  申请人：St. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

  公开号：US20160324874A1

  公开（公告）日：2016-11-10

  The invention is directed to the use of Retinoid X Receptor-gamma (RXR-gamma) agonists and Retinoid X Receptor-alpha (RXR-alpha) antagonists in treatment of cancer.